---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-005355"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:58:19.671840+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioCardia freezes primary outcomes data in Phase 3 CardiAMP HF trial; results at ACC 2025

## Summary
- Source data verified and data frozen for 115 patients in double-blind, placebo-controlled Phase 3 trial for ischemic HFrEF.
- Data transferred to Statistical Data Analysis Center core laboratory for analysis.
- Results scheduled for Late-Breaking Clinical Trials symposium at ACC 2025 on March 30, 2025 in Chicago.
- CEO states the study is intended to support safety and effectiveness for US and Japan approvals and Helix delivery system approval.

## SEC filing metadata
- accession: 0001437749-25-005355
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774925005355/0001437749-25-005355-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774925005355/bcda20250227_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-005355
- JSON: https://secwatch.observer/filing/0001437749-25-005355.json
- Plain text: https://secwatch.observer/filing/0001437749-25-005355.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.